[article]
Titre : |
Thiamidol containing treatment regimens in facial hyperpigmentation : An international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study |
Type de document : |
document électronique |
Auteurs : |
W. G. Philipp-Dormston, Auteur ; A. Vila Echagüe, Auteur ; S. H. Pérez Damonte, Auteur ; J. Riedel, Auteur ; A. Filbry, Auteur ; K. Warnke, Auteur ; C. Lofrano, Auteur ; D. Roggenkamp, Auteur ; G. Nippel, Auteur |
Année de publication : |
2020 |
Article en page(s) : |
p. 377-387 |
Note générale : |
Bibliogr. |
Langues : |
Anglais (eng) |
Catégories : |
Dermo-cosmétologie Emulsions -- Emploi en cosmétologie Peau -- Physiologie Pigmentation, Troubles de la Rugosité Thiamidol Visage -- Soins et hygiène
|
Index. décimale : |
668.5 Parfums et cosmétiques |
Résumé : |
- Objective : Tyrosinase is the rate-limiting enzyme in melanogenesis. Thiamidol is the most potent inhibitor of human tyrosinase out of 50 000 tested compounds. In clinical studies, it was shown to improve facial hyperpigmentation, post-inflammatory hyperpigmentation and age spots significantly. To identify the optimal number of daily Thiamidol applications, we conducted a split-face study comparing the efficacy and tolerability of four-times with two-times daily application. Subsequently, we evaluated the efficacy and tolerability of a typical face care regimen containing Thiamidol in a real-world study.
- Methods : The split-face study was double-blind, randomized, controlled, including two Thiamidol containing products (serum and day care SPF 30). The serum was applied twice daily on one half of the face and the day care SPF30 twice-daily on the whole face. The real-world study was open-label, observational, including three Thiamidol containing products (day care SPF 30 in the morning, serum and night care in the evening). In both studies, subjects with mild-to-moderate facial hyperpigmentation applied the products over 12 weeks. Assessments included clinical and subjective grading of hyperpigmentation, skin condition, hemi-/modified MASI, chromameter and clinical photography.
- Results : In the split-face study (n = 34), hyperpigmentation, skin roughness and hMASI improved all significantly (P < 0.001) versus baseline, with first visible results after two weeks of twice-daily application. The four-times daily application led to significant improvement versus the two-times daily application. In the real-world study (n = 83), all evaluated parameters, including skin condition and chromametry (n = 30), improved significantly (P < 0.001) in comparison with baseline and the corresponding preceding visits. The subjects judged the cosmetic properties of the products positively. In both studies, the products were well tolerated.
- Conclusion : Four-times daily Thiamidol improves facial hyperpigmentation significantly more than two-times daily and is well tolerated by the subjects. The real-world study with a typical face care regimen containing Thiamidol shows improvement of facial hyperpigmentation and confirms tolerability. Furthermore, the data provide evidence for the suitability of this three-product Thiamidol regimen for day-to-day life. |
Note de contenu : |
- MATERIALS AND METHODS : Split-face study - Real-world study - Statistics
- RESULTS : Split-face study - Real-world study
- Table 1 : Overview of methods of the two studies (split-face and real-world)
- Table 2 : INCI composition of the test products
- Table 3 : Demographic characteristics of the subjects of both studies (splitface and real-world)
- Table 4 : Self-grading of product performance |
DOI : |
https://doi.org/10.1111/ics.12626 |
En ligne : |
https://drive.google.com/file/d/1qaZx6p66xka-JhsDsVVOmJVwNg88ZpiO/view?usp=shari [...] |
Format de la ressource électronique : |
Pdf |
Permalink : |
https://e-campus.itech.fr/pmb/opac_css/index.php?lvl=notice_display&id=35289 |
in INTERNATIONAL JOURNAL OF COSMETIC SCIENCE > Vol. 42, N° 4 (08/2020) . - p. 377-387
[article]
|